Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

expense (22,889) (22,499)

Research and development expense (12,585) (12,312)

Total pre-tax charges for stock-

based compensation expense (41,988) (40,707)

Tax benefit 12,537 12,432

Stock-based compensation expense,

net of tax $(29,451) $(28,275)

Diluted earnings per share and diluted weighted average shares outstanding

for the three months ended March 31, 2008 and 2007 were computed according

to the provisions of FAS 123R.

(2) Includes a charge of $(69,900)K recorded in February 2008 representing

the premium paid to purchase five million shares of Isis

Pharmaceuticals, Inc. common stock.

(3) For the three months ended March 31, 2007, includes a pre-tax gain of

$10,848K related to the sale of our entire investment in the common

stock of Therapeutic Human Polyclonals, Inc. in March 2007, which had

a zero cost basis.

(4) All periods reflect the adoption of Emerging Issues Task Force Issue

No. 04-8, "The Effect of Contingently Convertible Debt on Diluted

Earnings Per Share," or EITF 04-8. As a result of the adoption of EITF

04-8, the 9,686K shares issuable upon conversion of our $690.0 million

in principal of 1.25% convertible senior notes, which were issued in

December 2003, are now included in diluted weighted average shares

outstanding for purposes of computing diluted earnings per share,

unless the effect would be anti-dilutive. In accordance with EITF 04-

8, interest and debt fees related to these notes of $1.9 million, net

of tax, for both the three months ended March 31, 2008 and 2007, have

been added back to net income and 9,686K shares have
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biologics ... their offering. , The Global ... professional and in-depth study on the current state ... The report provides a basic overview of the ...
(Date:3/4/2015)... March 04, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... to Optimize the Management of Pain”. , The ... Medscape.com for the next year. The focus of ... to recognize inadequate pain treatments, integrate appropriate pain ...
(Date:3/4/2015)... 2015 Vegalab announced the acquisition of Ecowin, ... year. As part of the acquisition, Ecowin rebranded itself ... his role as CEO for the company,s Korea operations. ... work alongside Koo and oversee developments at the new ... Koo founded Ecowin in 2008 to ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... Hopitaux de Paris en ... «   SARAH   », qui compare   ... l,yttrium-90 avec le   sorafénib dans le carcinome ... atteints d,un cancer du foie avancé   ; ...
Breaking Biology Technology:Global Biologics and Biosimilars Industry Report 2015-2020 2Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... BALTIMORE, Sept. 13 Champions Biotechnology, Inc. (OTC Bulletin Board: ... of advanced preclinical platforms and tumor specific data to enhance ... for the fiscal 2011 first quarter ended July 31, 2010. ... in the Company,s Form 10-Q at www.championsbiotechnology.com . ...
... Berkeley Engineers at the University of California, Berkeley, ... that could one day give new meaning to the ... a material that functions like the human skin, which ... said Ali Javey, associate professor of electrical engineering and ...
... Corporation Reports First Quarter Fiscal 2011 Financial Results. Revenue Increases 23.8% to RMB71.7 ... ET September 10, 2010." /> China Cord Blood Corporation Reports First ... ... ...
Cached Biology Technology:Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 4Engineers make artificial skin out of nanowires 2Engineers make artificial skin out of nanowires 3China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 2China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 3China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 4China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 5China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 6China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 7China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 8China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 9China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 10China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 11China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 12
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... Speedy diagnosis of the temper and vital signs of ... humanity, says a distinguished partnership of international scientists urging ... 10 years. The Partnership for Observation of the ... are among profound concerns that must be better measured ...
... found that the children of mothers whose water supplies ... expression changes that may lead to cancer and other ... potential harmful effects of these prenatal exposures, the new ... to detect signs of arsenic contamination. This is ...
... Company Anticipates Acquisition Could More Than Double its Current ... the Medical and Healthcare Industry, SAN JOSE, Calif., ... a leading biometric and security,solutions provider, announced today the ... Medical Systems (OTC: CHSY), a company listed in,the US ...
Cached Biology News:Human safety, prosperity depend on better ocean observing system: Scientists 2Human safety, prosperity depend on better ocean observing system: Scientists 3Human safety, prosperity depend on better ocean observing system: Scientists 4Human safety, prosperity depend on better ocean observing system: Scientists 5Human safety, prosperity depend on better ocean observing system: Scientists 6Human safety, prosperity depend on better ocean observing system: Scientists 7Human safety, prosperity depend on better ocean observing system: Scientists 8MIT: Prenatal arsenic exposure detected in newborns 2MIT: Prenatal arsenic exposure detected in newborns 3Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 2Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 3Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 4